Chiome Bioscience Inc. announced that it has entered into an purchase agreement to issue 64,560 units of 19th stock acquisition rights and 32,280 units of 20th stock acquisition rights at a price of ¥171 yen per 19th stock acquisition right, ¥76 per 20th stock acquisition right for gross proceeds of ¥1,931,609,040 through third-party allotment on July 4, 2023. The stock acquisition rights are exercisable 19th Stock Acquisition Rights ¥175, 20th stock acquisition rights ¥247. There is no maximum strike price.

The minimum exercise price is ¥129. The transaction will include participation from Growth Capital and Barclays Bank. The transaction has been approved in the board of directors' meeting of the company.

The exercisable period of the stock acquisition rights will start from July 21, 2023 to July 22, 2025. The stock acquisition rights have a hold period and cannot be transferred without the company's approval.